G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

February 13, 2023

https://www.globenewswire.com/news-release/2023/02/13/2606444/0/en/G1-Therapeutics-Announces-Top-Line-Results-from-Pivotal-Phase-3-Trial-of-Trilaciclib-in-Patients-Receiving-Triplet-Therapy-with-FOLFOXIRI-Bevacizumab-for-Metastatic-Colorectal-Canc.html

– PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During Induction and Duration of Severe Neutropenia in Cycles 1 Through 4 –

Read more at globenewswire.com

Related news for (GTHX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.